Accelerating AXL targeting for TNBC therapy

Lohit Khera, Sima Lev

Research output: Contribution to journalArticlepeer-review


The tyrosine kinase receptor AXL of the TAM (TYRO3, AXL and MERTK) family is considered as a promising therapeutic target for different hematological cancers and solid tumors. AXL is involved in multiple pro-​tumorigenic processes including cell migration, invasion, epithelial-mesenchymal transition (EMT), and stemness, and recent studies demonstrated its impact on cancer metastasis and drug resistance. Extensive studies on AXL have highlighted its unique characteristics and physiological functions and suggest that targeting of AXL could be beneficial in combination with chemotherapy, radiotherapy, immunotherapy, and targeted therapy. In this mini review, we discuss possible outcomes of AXL targeting either alone or together with other therapeutic agents and emphasize its impact on triple negative breast cancer (TNBC).
Original languageEnglish
Article number106057
Number of pages7
JournalThe international journal of biochemistry & cell biology
StatePublished - 14 Aug 2021


Dive into the research topics of 'Accelerating AXL targeting for TNBC therapy'. Together they form a unique fingerprint.

Cite this